Skip to main content
. Author manuscript; available in PMC: 2022 Oct 30.
Published in final edited form as: Eur J Cancer. 2022 Jan 19;163:108–118. doi: 10.1016/j.ejca.2021.12.024

Table 2.

Baseline laboratory variables of cases and controls. Cases: patients treated with a renin–angiotensin–aldosterone system inhibitors for hypertension. Controls: patients treated with non–renin–angiotensin–aldosterone system inhibitors for hypertension.

Cases (N = 3426) Controls (N = 2484) P Value
Data available Mean SD Data available Mean SD
Haemoglobin (g/dL) 2659 11.87 1.97 1917 11.92 1.91 <.001
White blood count (thousand/uL) 2567 7.94 9.00 1916 7.81 5.32 <.001
Creatinine 3113 1.03 0.58 2231 0.94 0.41 <.001
Total cholesterol (mg/dL) 927 162.3 42.8 511 170.8 47.0 <.001
Low-density lipoprotein (mg/dL) 854 85.48 33.6 462 94.59 35.64 <.001
High-density lipoprotein (mg/dL) 856 49.35 17.33 459 50.75 18.54 <.001